The stock of Jaguar Health Inc. (NASDAQ:JAGX) on Tuesday traded at $2.03. The last five days have seen an average of 2,569,350 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$0.42. The average number of shares traded over the last 20 days was 1,488,403, while the average volume over the last 50 days totaled 1,623,393.
JAGX stock dropped -9.82% since last month. On 10/22/21, the company’s shares reached a one-month low of $1.81. The stock touched a high of $13.41 on 01/08/21, after rallying from a low of $0.56 in 52 weeks. The price of JAGX stock has declined by -17.38% or -$0.42 this year, reaching a new high 3 times. Still, the stock price is down -84.87% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 144 days since Jaguar Health Inc. (JAGX) last reported insider trading activity on Jun 04. On Jun 04, Director BOCHNOWSKI JAMES J sold 152 shares at $1.74 each. This transaction resulted in the insider making $264. On Jun 03, BOCHNOWSKI JAMES J sold 292 shares at a price of US$1.75. After the transaction, the insider now owns 954,542 shares.
Beta for the stock is 1.53. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 14.45, the price-to-book (PB) ratio of 2.85.
For the three months ended June 29, Jaguar Health Inc.’s quick ratio was 3.20, while its current ratio was 3.50, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.76, and the total debt to equity ratio is 0.80. As far as profitability goes, gross margin for the trailing twelve months is 59.60% percent. Based on annual data, it had gross profit of $6.11 million and revenue of $9.38 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. JAGX’s return on assets (ROA) during the last 12 months has been -84.20%. There was a -85.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -220.40%. ROE has averaged -68.79 in the past year for the broader industry.
According to Jaguar Health Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.39 million, while revenues fell by -712.82% to $1.24 million. It was predicted that Jaguar Health Inc.’s quarterly earnings would be -$0.1, but it ended up being -$0.04. EBITDA was -$9.92 million for the quarter. At the end of Jaguar Health Inc.’s most recent quarter ended June 29, its liabilities totaled 37.75 million, while its total debt was $26.45 million. Equity owned by shareholders amounts to $46.48 million.
Here’s a quick look at Jaguar Health Inc.’s (JAGX) price momentum from a technical perspective. As of 25 October, the RSI 9-day stood at 46.07%, suggesting the stock is Neutral, with a 72.96% historical volatility rate.
The stochastic %K and %D were 44.97% and 31.23% respectively, while the average true range (ATR) was 0.13. Based on the 14-day stochastic reading of 60.02%, the RSI (14) reading is 40.10%. On the 9-day MACD Oscillator, the stock is at -0.03, and the 14-day reading is at -0.07.
In its analyst report released on July 07, 2021, Cantor Fitzgerald began covering Jaguar Health Inc. (NASDAQ: JAGX). The stock was rated as an Overweight by the brokerage firm. Analysts have assigned Jaguar Health Inc. (JAGX) an Buy rating. JAGX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 2 others recommend it as a buy.
What is JAGX’s price target for the next 12 months?
The current consensus forecast for the stock is between $13.00 and $15.00, with a median target price of $14.00. In analyzing these forecasts, the average price target given by analysts for Jaguar Health Inc. (JAGX) is $14.00.